Zejula
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
GSK’s Zejula slows disease progression in a range of ovarian cancers
October 2, 2019Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma
At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
Tesaro secures EU approval in specific ovarian cancer population
November 23, 2017Sales and Marketing Europe, European Commission, Tesaro, Zejula, pharma
The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged. Zejula is a poly (ADP-ribose) …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
